BIOLIFE SOLUTIONS INC (BLFS) Stock Fundamental Analysis
USA - NASDAQ:BLFS - US09062W2044 - Common Stock
28.79 USD
+0.13 (+0.45%)
28.22 USD
-0.57 (-1.98%)
We assign a fundamental rating of 4 out of 10 to BLFS. BLFS was compared to 58 industry peers in the Life Sciences Tools & Services industry. BLFS has a great financial health rating, but its profitability evaluates not so good. BLFS is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
BLFS had positive earnings in the past year.
BLFS had a positive operating cash flow in the past year.
BLFS had negative earnings in 4 of the past 5 years.
In multiple years BLFS reported negative operating cash flow during the last 5 years.
1.2 Ratios
The Return On Assets of BLFS (-1.43%) is comparable to the rest of the industry.
The Return On Equity of BLFS (-1.59%) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.43% | ||
| ROE | -1.59% | ||
| ROIC | N/A |
ROA(3y)-17.53%
ROA(5y)-10.68%
ROE(3y)-21.44%
ROE(5y)-13.06%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Gross Margin value of 66.32%, BLFS belongs to the best of the industry, outperforming 89.47% of the companies in the same industry.
BLFS's Gross Margin has been stable in the last couple of years.
BLFS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 66.32% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y28.1%
GM growth 5Y-0.79%
2. Health
2.1 Basic Checks
BLFS does not have a ROIC to compare to the WACC, probably because it is not profitable.
BLFS has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, BLFS has more shares outstanding
BLFS has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 19.89 indicates that BLFS is not in any danger for bankruptcy at the moment.
BLFS has a better Altman-Z score (19.89) than 100.00% of its industry peers.
There is no outstanding debt for BLFS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 29.48 | ||
| Altman-Z | 19.89 |
ROIC/WACCN/A
WACC10.5%
2.3 Liquidity
BLFS has a Current Ratio of 4.43. This indicates that BLFS is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of BLFS (4.43) is better than 68.42% of its industry peers.
BLFS has a Quick Ratio of 3.45. This indicates that BLFS is financially healthy and has no problem in meeting its short term obligations.
BLFS's Quick ratio of 3.45 is fine compared to the rest of the industry. BLFS outperforms 66.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.43 | ||
| Quick Ratio | 3.45 |
3. Growth
3.1 Past
BLFS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 115.04%, which is quite impressive.
The Revenue for BLFS has decreased by -24.62% in the past year. This is quite bad
Measured over the past years, BLFS shows a very strong growth in Revenue. The Revenue has been growing by 24.59% on average per year.
EPS 1Y (TTM)115.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%98%
Revenue 1Y (TTM)-24.62%
Revenue growth 3Y-11.63%
Revenue growth 5Y24.59%
Sales Q2Q%-10.26%
3.2 Future
Based on estimates for the next years, BLFS will show a very strong growth in Earnings Per Share. The EPS will grow by 43.26% on average per year.
BLFS is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 16.24% yearly.
EPS Next Y28%
EPS Next 2Y47.99%
EPS Next 3Y43.26%
EPS Next 5YN/A
Revenue Next Year-5.39%
Revenue Next 2Y4.22%
Revenue Next 3Y9.87%
Revenue Next 5Y16.24%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 143.95, the valuation of BLFS can be described as expensive.
Compared to the rest of the industry, the Price/Earnings ratio of BLFS is on the same level as its industry peers.
BLFS is valuated expensively when we compare the Price/Earnings ratio to 26.89, which is the current average of the S&P500 Index.
A Price/Forward Earnings ratio of 297.11 indicates a quite expensive valuation of BLFS.
BLFS's Price/Forward Earnings is on the same level as the industry average.
The average S&P500 Price/Forward Earnings ratio is at 22.99. BLFS is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 143.95 | ||
| Fwd PE | 297.11 |
4.2 Price Multiples
BLFS's Enterprise Value to EBITDA ratio is in line with the industry average.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of BLFS is on the same level as its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 4044.95 | ||
| EV/EBITDA | 294.28 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
A more expensive valuation may be justified as BLFS's earnings are expected to grow with 43.26% in the coming years.
PEG (NY)5.14
PEG (5Y)N/A
EPS Next 2Y47.99%
EPS Next 3Y43.26%
5. Dividend
5.1 Amount
BLFS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
28.79
+0.13 (+0.45%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners104.58%
Inst Owner Change-0.44%
Ins Owners2.2%
Ins Owner Change-0.14%
Market Cap1.38B
Revenue(TTM)91.34M
Net Income(TTM)-5530000
Analysts83.75
Price Target31.93 (10.91%)
Short Float %7.87%
Short Ratio8.91
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)77%
Min EPS beat(2)72.55%
Max EPS beat(2)81.45%
EPS beat(4)4
Avg EPS beat(4)176.37%
Min EPS beat(4)55%
Max EPS beat(4)496.49%
EPS beat(8)7
Avg EPS beat(8)64.23%
EPS beat(12)7
Avg EPS beat(12)-13.03%
EPS beat(16)10
Avg EPS beat(16)-4.16%
Revenue beat(2)2
Avg Revenue beat(2)5.37%
Min Revenue beat(2)5.11%
Max Revenue beat(2)5.63%
Revenue beat(4)4
Avg Revenue beat(4)7.86%
Min Revenue beat(4)3.34%
Max Revenue beat(4)17.36%
Revenue beat(8)6
Avg Revenue beat(8)7.76%
Revenue beat(12)7
Avg Revenue beat(12)2.64%
Revenue beat(16)10
Avg Revenue beat(16)2.07%
PT rev (1m)0%
PT rev (3m)0.25%
EPS NQ rev (1m)0%
EPS NQ rev (3m)56.24%
EPS NY rev (1m)-1.21%
EPS NY rev (3m)-272.4%
Revenue NQ rev (1m)0.01%
Revenue NQ rev (3m)4.61%
Revenue NY rev (1m)-0.34%
Revenue NY rev (3m)3.66%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 143.95 | ||
| Fwd PE | 297.11 | ||
| P/S | 15.1 | ||
| P/FCF | 4044.95 | ||
| P/OCF | 88.75 | ||
| P/B | 3.97 | ||
| P/tB | 10.89 | ||
| EV/EBITDA | 294.28 |
EPS(TTM)0.2
EY0.69%
EPS(NY)0.1
Fwd EY0.34%
FCF(TTM)0.01
FCFY0.02%
OCF(TTM)0.32
OCFY1.13%
SpS1.91
BVpS7.25
TBVpS2.64
PEG (NY)5.14
PEG (5Y)N/A
Graham Number5.71
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.43% | ||
| ROE | -1.59% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 66.32% | ||
| FCFM | 0.37% |
ROA(3y)-17.53%
ROA(5y)-10.68%
ROE(3y)-21.44%
ROE(5y)-13.06%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y28.1%
GM growth 5Y-0.79%
F-Score6
Asset Turnover0.24
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 29.48 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 223.97% | ||
| Cap/Sales | 16.64% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 363.64% | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.43 | ||
| Quick Ratio | 3.45 | ||
| Altman-Z | 19.89 |
F-Score6
WACC10.5%
ROIC/WACCN/A
Cap/Depr(3y)80.15%
Cap/Depr(5y)101.86%
Cap/Sales(3y)10.07%
Cap/Sales(5y)11.77%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)115.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%98%
EPS Next Y28%
EPS Next 2Y47.99%
EPS Next 3Y43.26%
EPS Next 5YN/A
Revenue 1Y (TTM)-24.62%
Revenue growth 3Y-11.63%
Revenue growth 5Y24.59%
Sales Q2Q%-10.26%
Revenue Next Year-5.39%
Revenue Next 2Y4.22%
Revenue Next 3Y9.87%
Revenue Next 5Y16.24%
EBIT growth 1Y92.48%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year328.14%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y101.98%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y1539.07%
OCF growth 3YN/A
OCF growth 5Y47.44%
BIOLIFE SOLUTIONS INC / BLFS FAQ
What is the ChartMill fundamental rating of BIOLIFE SOLUTIONS INC (BLFS) stock?
ChartMill assigns a fundamental rating of 4 / 10 to BLFS.
What is the valuation status for BLFS stock?
ChartMill assigns a valuation rating of 2 / 10 to BIOLIFE SOLUTIONS INC (BLFS). This can be considered as Overvalued.
Can you provide the profitability details for BIOLIFE SOLUTIONS INC?
BIOLIFE SOLUTIONS INC (BLFS) has a profitability rating of 2 / 10.
What is the financial health of BIOLIFE SOLUTIONS INC (BLFS) stock?
The financial health rating of BIOLIFE SOLUTIONS INC (BLFS) is 8 / 10.
Can you provide the dividend sustainability for BLFS stock?
The dividend rating of BIOLIFE SOLUTIONS INC (BLFS) is 0 / 10 and the dividend payout ratio is 0%.